Crohn’s Disease Stem Cell Transplantation Program

Gastroenterology and Inflammatory Bowel Disease
Crohn’s Disease Stem Cell Transplantation Program
Organizational unit: Department
Hematology-Oncology, Infectious Diseases, Palliative Care, Psychology, and Nutrition
Crohn’s Disease Stem Cell Transplantation Program
Organizational unit: Department
Stem Cell Transplantation
Crohn’s Disease Stem Cell Transplantation Program
Organizational unit: Department

139155 Citations
166 h-index
1297 Article
295 Review article
105 Letter
71 Comment/debate
More

Adherent-invasive Escherichia coli in Crohn’s disease: the 25th anniversary
AIEC Research Group, 1 Feb 2026, In: Gut. 75, 2, p. 411-424 14 p.
Research output: Contribution to journal › Article › peer-review

Open Access
6 Scopus citations
A Phase 2 Study of MORF-057, an Oral α4β7 Integrin Inhibitor in Moderately to Severely Active Ulcerative Colitis
Sands, B. E., Schreiber, S., Danese, S., Kierkus, J., Abhyankar, B., Choi, M. Y., Soo, C., Wu, Y., Sun, F., Lee, D., Cui, D., Mangada, M., Singhal, P., Hussain, A., Rogers, B. N., Peyrin-Biroulet, L. & Feagan, B. G., Feb 2026, In: Clinical Gastroenterology and Hepatology. 24, 2, p. 525-534 10 p.
Research output: Contribution to journal › Article › peer-review

Open Access
2 Scopus citations
A pilot genome-wide association study of collagen deposition in collagenous colitis
Di Lorenzo, B., Zheng, T., Rieder, F., Colombel, J. F., Peter, I., Kupcinskas, J., Ohlsson, B., Ferrer Cassado, C., Zabana, Y., Münch, A., Jančiauskas, D., Gordon, I. O., D’Amato, M. & Roda, G., 1 Feb 2026, In: Gastroenterology Report. 14, goaf105.
Research output: Contribution to journal › Article › peer-review

Open Access
A Primer for Discussing Complementary and Integrative Medicine in Gastroenterology Settings
Thakur, E. R., Craven, M., Keefer, L. & Hass, D. J., Apr 2026, In: Neurogastroenterology and Motility. 38, 4, e70313.
Research output: Contribution to journal › Review article › peer-review
Artificial intelligence differentiates prefibrotic primary myelofibrosis with thrombocytosis from essential thrombocythemia using digitized bone marrow biopsy images
Srisuwananukorn, A., Loscocco, G. G., Dolezal, J. M., Kuykendall, A. T., Santi, R., Zhang, L., Singh, A. M., Guglielmelli, P., Vannucchi, A. M., Salama, M. E., Pearson, A. T. & Hoffman, R., 2026, (Accepted/In press) In: Leukemia.
Research output: Contribution to journal › Article › peer-review

Open Access
Automating clinical phenotyping using natural language processing
Schmidt, L., Ibing, S., Borchert, F., Hugo, J., Marshall, A. A., Peraza, J., Cho, J. H., Böttinger, E. P., Renard, B. Y. & Ungaro, R. C., Dec 2026, In: Communications Medicine. 6, 1, 77.
Research output: Contribution to journal › Article › peer-review

Open Access
B Cell Dysregulation in IBD: From Pathophysiology to Therapeutic Targeting
Jha, D. & Mehandru, S., 1 Apr 2026, In: Inflammatory Bowel Diseases. 32, 4, p. 830-833 4 p.
Research output: Contribution to journal › Editorial
Benefit–risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn’s disease
Vermeire, S., Colombel, J. F., Danese, S., Panaccione, R., Peyrin-Biroulet, L., Beck, K., Chaparro, M., Gisbert, J. P., Dubcenco, E., Klaff, J., Naling, G., Ford, S., Remple, V., Joshi, N., Suravaram, S., Duncan, B., Wang, Y., Wick-Urban, B. & Loftus, E. V., 1 Jan 2026, In: Journal of Crohn's and Colitis. 20, 1, jjaf198.
Research output: Contribution to journal › Article › peer-review

Open Access
1 Scopus citations
Biopsychosocial and Environmental Factors That Impact Brain-Gut-Microbiome Interactions in Obesity
Sood, R., Kilpatrick, L. A., Keefer, L. A. & Church, A., Jan 2026, In: Clinical Gastroenterology and Hepatology. 24, 1, p. 10-20 11 p.
Research output: Contribution to journal › Review article › peer-review

Open Access
3 Scopus citations
Biopsychosocial Aspects of Adult and Pediatric Disorders of Gut-Brain Interaction
Elsenbruch, S., Ballou, S., Keefer, L., Murphy, T. B., Van Oudenhove, L., van Tilburg, M. A. L., Vasant, D. H. & Levy, R. L., 1 May 2026, In: Gastroenterology. 170, 6, p. 1205-1223 19 p.
Research output: Contribution to journal › Review article › peer-review

Open Access
2 Scopus citations
Bowel Urgency in Crohn’s Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Study
Jairath, V., D’Haens, G., Sands, B. E., Travis, S., Chaparro, M., Peyrin-Biroulet, L., Chen, M. H., Dubinsky, M., Ferrante, M., Schreiber, S., McGinnis, K., Vadhariya, A., Appelmans, S., Lin, Z., Yu, G., Protic, M., Moses, R. & Ghosh, S., Feb 2026, In: Clinical Gastroenterology and Hepatology. 24, 2, p. 463-473.e5
Research output: Contribution to journal › Article › peer-review

Open Access
Combination Therapy of Resilience Intervention with Biologics in Crohn's Disease (CATHARSIS): Study protocol for a randomized controlled trial
Keefer, L., Ungaro, R., Lewis, A., Lee, J., de Amorrortu, C., Lores, T., Siganporia, T., Mehandru, S., Petralia, F. & Colombel, J. F., Jan 2026, In: Contemporary Clinical Trials. 160, 108151.
Research output: Contribution to journal › Article › peer-review
1 Scopus citations

Weekly Summary: Johnson & Johnson (NYSE:JNJ) falls for a fifth consecutive week, a five-week fall of 9%; -$5.87 [2.6%]
Sands, B. E.
9/05/26
1 item of Media coverage
Press/Media
Update on Funding & Suspension of Trading
Keefer, L. & Dubinsky, M.
8/05/26
1 item of Media coverage
Press/Media
Lilly's Omvoh is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years
Colombel, J.-F.
5/05/26 → 8/05/26
8 items of Media coverage
Press/Media
Johnson & Johnson (NYSE: JNJ) Posts DUET Data Showing JNJ-4804 Delivers Higher Remission in Refractory IBD
Sands, B. E.
8/05/26
1 item of Media coverage
Press/Media
Johnson & Johnson climbs 8.1% in 2026, highest gainer in Pharmaceuticals sector
Sands, B. E.
8/05/26
1 item of Media coverage
Press/Media
Johnson & Johnson (NYSE:JNJ) slips 2.6% in Week 18 of 2026: Latest News and Company Communication
Sands, B. E.
8/05/26
1 item of Media coverage
Press/Media
Johnson & Johnson (NYSE:JNJ) in negative territory today, declining 0.4%; -$1 [-0.4%]
Sands, B. E.
8/05/26
1 item of Media coverage
Press/Media
Mirikizumab Demonstrates Sustained Disease Clearance Through 4 Years in Ulcerative Colitis
Colombel, J.-F.
7/05/26
1 item of Media coverage
Press/Media
Johnson & Johnson Investigational Co-Antibody Therapy JNJ-4804 Shows Potential to Raise the Bar for Clinical Efficacy in Treating Refractory Inflammatory Bowel Disease
Abreu,, M. & Sands, B. E.
5/05/26 → 7/05/26
11 items of Media coverage
Press/Media
Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease
Abreu,, M. & Sands, B. E.
5/05/26 → 7/05/26
2 items of Media coverage
Press/Media
Lilly’s Omvoh demonstrates durable disease clearance in ulcerative colitis through four years
Colombel, J.-F.
5/05/26 → 6/05/26
2 items of Media coverage
Press/Media
Lilly's Omvoh is the first and only IL─23p19 to demonstrate durable disease clearance in ulcerative colitis through four years
Colombel, J.-F.
6/05/26
1 item of Media coverage
Press/Media